Circular <scp>RNA</scp> 0068669 as a new biomarker for hepatocellular carcinoma metastasis

Yao, Ting; Chen, Qingqing; Shao, Zhouwei; Song, Zhihua; Fu, Liyun; Xiao, Bingxiu

doi:10.1002/jcla.22572

Cited by 33 publications

(24 citation statements)

References 34 publications

(73 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the included publications, a total of 43 articles on 64 studies were analyzed involving 10,123 subjects in Table . Of the 64 studies, five studies focused on colorectal cancer (Ji et al, ; Wang, Li, et al, ; Wang et al, ; Zhang, Yang, et al, ; Zhuo, Lin, Chen, Huang, & Hu, ), 10 on breast cancer (Lu et al, ; Yin et al, ), 22 on gastric cancer (Chen, Li, Zhao, Xiao, & Guo, ; Huang, He, Liang, Huang, & Zhu, ; Li, et al, , ; Li, Shao, et al, ; Li, Song, et al, ; Lu et al, ; Lu, Shao, Ye, Xiao, & Guo, ; Shao, Chen, et al, ; Shao, Li, et al, ; Shao, Yang, et al, ; Sun, Tang, et al, ; Tian, Chen, Li, & Xiao, ; Wei et al, ; Xie et al, ; Zhao, Chen, Li, Xiao, & Zhang, ), four on lung cancer (Li, Wang, Chen, Chen, & Jin, ; Zhu et al, ; Zong et al, ), 16 on hepatocellular carcinoma (Chen, Zhang, Lin, Song, & Wang, ; Fu et al, , ; Li et al, ; Qin et al, ; Shang et al, ; Yao et al, ; Yao et al, ; Zhang, Zhang, Lin, & Wang, ; Zhang, Zhou, et al, ; Zhang, Xu, et al, ) and seven on other cancers (Fan, Cao, Liu, Zhang, & Li, ; Lan et al, ; Li et al, ; Sun, Li, et al, ; Teng et al, ; Wang, Xue, et al, ; Yang et al, ). Moreover, three articles with 13 studies explored the diagnostic value of the combined circRNAs (Chen, Li, Zhao, et al, ; Fan et al, ; Li, Shao, et al, ) in Table .…”

Section: Resultsmentioning

confidence: 99%

“…Among the included publications, a total of 43 articles on 64 studies were analyzed involving 10,123 subjects in Table S1. Of the 64 studies, five studies focused on colorectal cancer (Ji et al, 2018;Wang, Li, et al, 2018;Wang et al, 2015;Zhang, Yang, et al, 2018;Zhuo, Lin, Chen, Huang, & Hu, 2017), 10 on breast cancer Yin et al, 2018), 22 on gastric cancer (Chen, Li, Zhao, Xiao, & Guo, 2017;Huang, He, Liang, Huang, & Zhu, 2017;Li, Shao, et al, 2018;Li, Song, et al, 2017;Lu et al, 2018;Shao, Chen, et al, 2017;Shao, Li, et al, 2017;Sun, Tang, et al, 2018;Tian, Chen, Li, & Xiao, 2018;Wei et al, 2019;Xie et al, 2018;Zhao, Chen, Li, Xiao, & Zhang, F I G U R E 1 The flow diagram of this meta-analysis 2018), four on lung cancer (Li, Wang, Chen, Chen, & Jin, 2018;Zhu et al, 2017;Zong et al, 2018), 16 on hepatocellular carcinoma (Chen, Zhang, Lin, Song, & Wang, 2018;Fu et al, 2018Fu et al, , 2017Li et al, 2019;Qin et al, 2016;Shang et al, 2016;Yao et al, 2017;Yao et al, 2018;Zhang, Zhou, et al, 2018; and seven on other cancers (Fan, Cao, Liu, Zhang, & Li, 2019;Lan et al, 2018;Li et al, 2019;Sun, Li, et al, 2018;…”

Section: Study Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic performance of circular RNAs in human cancers: A systematic review and meta‐analysis

et al. 2019

Molec Gen & Gen Med

View full text Add to dashboard Cite

Background Recently, accumulating evidence have revealed that circular RNA (circRNA) was deregulated in multiple types of cancer, suggesting that circRNA might serve as a novel candidate biomarker of cancer diagnosis. However, inconsistent results have become an obstacle in applying circRNAs to clinical practice. The aim of this study is to evaluate diagnostic value of circRNAs among cancers. Methods A literature search was systematically performed among PubMed, Sciencedirect, Cochrane Library, Web of Science, Wanfang, and Chinese National Knowledge Infrastructure databases up to February 15, 2019. The pooled sensitivity (SEN), specificity (SPE), positive likelihood ratios, negative likelihood ratios, diagnostic odds ratio, and area under the SROC curve (AUC) were applied to evaluate diagnostic performance of circRNAs. Results In total, the study included 64 studies with single circRNA and 13 studies with combined circRNAs. Overall, the study presented that a single circRNA had moderate diagnostic value, with a SEN of 0.75, a SPE of 0.76, and an AUC of 0.82. The plasma circRNAs had higher diagnostic accuracy than tissue (AUC: 0.87, 95% confidence interval [CI]: 0.83–0.89 for plasma/serum subgroup; AUC: 0.79, 95% CI: 0.75–0.82 for tissue subgroup). Furthermore, the combined circRNAs had good diagnostic efficacy for GC, with a SEN of 0.89, a SPE of 0.94, and an AUC of 0.97, respectively. Conclusion This study confirmed that circRNAs may be candidate biomarkers for cancer diagnosis. In particular, diagnosis of combined circRNAs will be a new alternative applied to clinical research and practice for cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

Diagnostic performance of circular RNAs in human cancers: A systematic review and meta‐analysis

et al. 2019

Molec Gen & Gen Med

View full text Add to dashboard Cite

show abstract

“…Until now, there are only preliminary investigations focusing on the role of circRNAs in cancers . Existing evidence demonstrates that circRNA expression is abnormal expressed in tumor tissues compared with adjacent tissues, and associated with clinical outcomes in patients with tumors . For example, CircRNA PTPRM expression is significantly increased in HCC tissues compared with paired adjacent tissues, and its overexpression is correlated with HCC recurrence and metastasis in HCC patients .…”

Section: Discussionmentioning

confidence: 99%

Circular RNA SMARCA5 correlates with favorable clinical tumor features and prognosis, and increases chemotherapy sensitivity in intrahepatic cholangiocarcinoma

Fang

2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Objective: This present study aimed to investigate the correlation of circular RNA SMARCA5 (circ-SMARCA5) with clinicopathological features and overall survival (OS), and the effect of circ-SMARCA5 on cell proliferation and chemotherapy sensitivity to cisplatin/gemcitabine in intrahepatic cholangiocarcinoma (ICC). Methods:Totally 92 primary ICC patients who underwent resection were recruited, and their tumor tissues and adjacent tissues were collected for circ-SMARCA5 detection. The effect of circ-SMARCA5 on cell proliferation and chemotherapy sensitivity was detected after circ-SMARCA5 overexpression plasmid transfection into TFK-1 and HuH-28 ICC cells.Results: Circ-SMARCA5 expression was reduced in ICC tumor tissues compared to adjacent tissues. Tumor circ-SMARCA5 high expression was negatively associated with Eastern Cooperative Oncology Group performance score, T stage, N stage, TNM stage, and abnormal CA199 status. Furthermore, OS was increased in patients with tumor circ-SMARCA5 high expression compared with those with low expression, and further multivariate Cox's regression demonstrated that tumor circ-SMARCA5 high expression was an independent predictive factor for longer OS. In TFK-1 and HuH-28 ICC cells, circ-SMARCA5 upregulation decreased cell proliferation, reduced relative cell viability in cisplatin-treated as well as gemcitabine-treated cells, and also decreased inhibitory concentration by 50% value (IC 50 ) of cisplatin and gemcitabine. Conclusion:The correlation of circ-SMARCA5 with favorable clinical tumor features, survival profile, and its promoting effect on chemotherapy sensitivity implies its potential as a valuable biomarker in monitoring disease progression and prognosis of ICC. K E Y W O R D Scell proliferation, chemotherapy sensitivity, circular RNA SMARCA5, intrahepatic cholangiocarcinoma, prognosis

show abstract

“…The relative quantification levels of hsa_circ_0067582 were calculated using the ΔC q (quantification cycle) method . A higher ΔC q value indicated a lower expression level . Through three independent rigorous experiments, all of data were expressed by mean ± standard deviation (SD).…”

Section: Methodsmentioning

confidence: 99%

“…26 A higher ΔCq value indicated a lower expression level. 27 Through three independent rigorous experiments, all of data were expressed by mean ± standard deviation (SD). The data in this article are in accordance with the normal distribution.…”

Section: Qrt-pcr Ulteriorly Detection Of Hsa_ Circ_0067582mentioning

confidence: 99%

Reduced expression of circRNA hsa_circ_0067582 in human gastric cancer and its potential diagnostic values

Ding

Yang

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Gastric cancer (GC) is one of the global mortality diseases and has a poor prognosis due to the lack of ideal tumor biomarkers. Circular RNAs (circRNAs) are an abundant kind of endogenous RNAs that recently are found play a crucial role in the cancer occurrence and development. Nevertheless, little is known with regard to the diagnostic values of these circRNAs for GC. In this article of research, we investigated the role of hsa_circ_0067582 in clinical diagnosis of GC. Materials and Methods We used divergent primers, and the expression levels of hsa_circ_0067582 in 93 fresh GC tissues and paired adjacent normal tissues from surgical patients were detected using quantitative reverse transcription‐polymerase chain reaction (qRT‐PCR). Then, a receiver operating characteristic (ROC) curve was established to assess the diagnostic significance of hsa_circ_0067582. The relationship between expression of hsa_circ_0067582 and clinicopathological factors of patients was made further explored. Results Hsa_circ_0067582 levels were significantly decreased in GC tissues contrasted with adjacent normal tissues (n = 93, P < .001). After that, we discovered that it was evidently downregulated in 81.7% (76/93) GC tissues. The area under the ROC curve (AUC) of hsa_circ_0067582 was up to 0.6937, the sensitivity was 66.67%, and the specificity was 61.29%. Moreover, the hsa_circ_0067582 levels were obviously associated with tumor diameter (P = .002) and carbohydrate antigen 19‐9 (CA19‐9, P = .01). Meanwhile, after operation, low‐level group of hsa_circ_0067582 of GC patients was associated with better prognosis. Conclusion Our data imply that hsa_circ_000067582 may be a potential biomarker for GC diagnosis and prognosis evaluation.

show abstract

Circular RNA 0068669 as a new biomarker for hepatocellular carcinoma metastasis

Abstract: Our findings indicate that hsa_circ_0068669 might be served as a novel potential biomarker for HCC metastasis.

Cited by 33 publications

References 34 publications

Diagnostic performance of circular RNAs in human cancers: A systematic review and meta‐analysis

Diagnostic performance of circular RNAs in human cancers: A systematic review and meta‐analysis

Circular RNA SMARCA5 correlates with favorable clinical tumor features and prognosis, and increases chemotherapy sensitivity in intrahepatic cholangiocarcinoma

Reduced expression of circRNA hsa_circ_0067582 in human gastric cancer and its potential diagnostic values

Contact Info

Product

Resources

About